Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials.
Journal Title: Pharmacological Reports - Year 2006, Vol 58, Issue 0
Abstract
There is a growing clinical evidence to support the hypothesis that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase is a new independent cardiovascular risk factor. ADMA mediates endothelial dysfunction in lipid disorders, coronary artery disease, chronic heart failure, diabetes mellitus and hypertension. The aim of this review was to summarize the latest evidence from epidemiological and prospective clinical trials and to emphasize the role of ADMAas a cardiovascular risk factor.
Authors and Affiliations
Andrzej Szuba, Maciej Podgórski
Keywords
Related Articles
- EP ID EP96570
- DOI -
- Views 89
- Downloads 0
Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats.
In the present study, we investigated the influence of repeated treatment with fluoxetine (FLU, 5 or 10 mg/kg) and amantadine (AMA, 10 mg/kg), given separately or jointly (twice daily for 14 day), at the mRNA level (the...
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population.
Traditional (t) non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors (coxibs) are important and efficacious drugs for the management of musculoskeletal symptoms. These drugs have...
No association of three GRIN2B polymorphisms with lithium response in bipolar patients.
We investigated three polymorphisms in the NMDA receptor 2B subunit gene (GRIN2B) as a candidate gene for lithium response involved in glutamatergic neurotransmission. One hundred five bipolar patients treated with lithi...
Hippocampus, hippocampal sclerosis and epilepsy.
Hippocampal sclerosis (HS) is considered one of the major pathogenic factors of drug-resistant temporal lobe epilepsy. HS is characterized by selective loss of pyramidal neurons - especially of sectors CA1 and CA3 of the...
Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes.
The main objective of the study was to develop an alternative non-genetic rat model for type 2 diabetes (T2D). Six-week-old male Sprague-Dawley rats (190.56 ± 23.60 g) were randomly divided into six groups, namely: Norma...